RxDoctor Payments Data

Alexander Grand, MD

Ophthalmology · Sacramento, CANPI 1861694077

Payments from drug & device makers

$5,167in general payments, 2019–2025

Across 292 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$994
  • Bausch & Lomb Americas Inc.$911
  • Novartis$609
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$556
  • Sun Pharmaceutical Industries Inc.$477
  • Alcon$436
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$5,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,167 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$551,413
Medicare patients
1,355
Services billed
14,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine143$197,171
MieboPerfluorohexyloctane/Pf59$71,793
XiidraLifitegrast47$68,425
LumiganBimatoprost82$44,954
CequaCyclosporine22$33,097
Cyclosporine46$27,062
TyrvayaVarenicline Tartrate29$20,027
Fluorometholone270$19,579
Azelastine Hcl603$18,876
VyzultaLatanoprostene Bunod29$18,148
Prednisolone Acetate132$8,728
Latanoprost789$7,937
CombiganBrimonidine Tartrate/Timolol17$7,779
Travoprost25$6,071
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha318$5,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$994$249,904242 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$911$158,366135 claims
Sun Pharmaceutical Industries Inc.Cequa$477$33,09722 claims
Oyster Point Pharma, Inc.Tyrvaya$133$20,02729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →